CLAIMS

1. A method for the treatment of inflammation or inflammatory-related disorder comprising administering to a mammal in need of such treatment an amount effective to ameliorate the symptoms of inflammation or inflammatory-related disorder of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

2. A method of stabilizing damaged cellular membranes which comprises administering to a mammal having damaged cellular membranes an amount effective to stabilize said damaged cellular membranes of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

3. A method of inhibiting oxidation of components of cell membranes of a mammal, which comprises administering to a mammal in need of such treatment an amount effective to inhibit oxidation of components of cell membranes of the mammal of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

4. A method of normalization of NO-synthetase activity in a mammal, which comprises administering to a mammal in need of such theatment an amount effective to normalize NO-synthetase activity in the mammal of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

5. A method of inhibiting thrombocyte aggregation, which comprises administering to a mammal in need of such treatment an amount effective to inhibit thrombocyte aggregation of ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

6. A method in accordance with claim 1, wherein said ribonucleic acid is administered in an amount within a range of from 0.1mg to 1g per kg weight of a mammal.

7. A method in accordance with claim 1, wherein said ribonucleic acid is obtained from a yeast.

8. A method in accordance with claim 6, wherein said ribonucleic acid is obtained from a *Saccharomyces cerevisiae*.

9. A method in accordance with claim 6, wherein said ribonucleic acid is obtained from a *Candida utilis*.

10. A method in accordance with claim 1, wherein said ribonucleic acid has a nitrogen content of more then 14.5% by weight.

11. A method in accordance with claim 1, wherein said ribonucleic acid has a phosphorus content of more then 8,5% by weight.

12. A method in accordance with claim 1, wherein said ribonucleic acid is administered by an intradermal, hypodermal, oral, intra-abdominal, intramuscular, or intravenous route, or is directly administered to a situs of the inflammation or inflammatory-related disorder.

13. A method in accordance with claim 1, wherein the inflammatory-related disorder is infarct.

14. A method in accordance with claim 1, wherein the inflammatory-related disorder is stroke.

15. A method in accordance with claim 1, wherein the inflammatory-related disorder is arthritis.

16. A method in accordance with claim 1, wherein the inflammatory-related disorder is allergy.

17. A method in accordance with claim 1, wherein the inflammatory-related disorder is pain.

18. A method in accordance with claim 1, wherein the inflammatory-related disorder is fever.

19. A method in accordance with claim 1, wherein the inflammatory-related disorder is swelling.

20. A pharmaceutical composition for the treatment or the prevention of inflammation or inflammatory-related disorder, comprising ribonucleic acid and a pharmaceutically acceptable vehicle, carrier, or diluent.

21. A pharmaceutical composition in accordance with claim 20, wherein said ribonucleic acid has a nitrogen content is more then 14.5% by weight.

22. A pharmaceutical composition in accordance with claim 20, wherein said ribonucleic acid has a phosphorus content of more then 8.5% by weight.

add B13 / add C27 60 add D67